Iovance Biotherapeutics, Inc. — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017; filed March 12, 2018. Q4 figures are included in the filing. Iovance is a clinical-stage biotechnology company developing autologous tumor-infiltrating lymphocyte (TIL) cancer therapies. It had no approved products and generated no revenue.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $71.6 million | $26.9 million |
| General and administrative expense | $21.3 million | $26.7 million |
| Net loss | $92.1 million | $52.9 million |
| Net loss per share, basic and diluted | $1.41 | $1.85 |
| Cash used in operating activities | $78.7 million | $32.7 million |
| Cash and cash equivalents at year-end | $145.4 million | $106.7 million |
| Working capital at year-end | $139.4 million | Not stated in the cited discussion |
| Total assets / total liabilities at year-end | $155.4 million / $9.9 million | $171.9 million / $5.0 million |
There was no revenue, so operating margins are not meaningful. The balance sheet reports current liabilities only and no debt line item. Cash increased by $38.7 million during 2017, supported by $53.7 million of net proceeds from the September equity offering; operating cash use rose substantially. The company reported $58.7 million of financing cash flow and $58.7 million of investing cash inflow, primarily from investment maturities. At December 31, 2017 it held no short-term investments.
Q4 2017 revenue was zero and net loss attributable to common stockholders was $25.9 million, or $0.36 per share. The corresponding Q4 2016 loss was $15.7 million, or $0.25 per share. The 2016 annual loss attributable to common stockholders included a $49.5 million non-cash deemed dividend from a preferred-stock beneficial conversion feature; this explains why 2016 per-share loss differs from net loss per share in the annual comparison.
Material changes and operating developments
- R&D expense rose 166% year over year, principally reflecting higher manufacturing and Gen 2 process-transfer costs, expanded clinical trials, increased staffing, and outside research services.
- G&A expense declined 20%, mainly because 2016 included substantial non-cash executive stock-compensation charges; legal fees increased in 2017.
- The company selected its Gen 2 manufacturing process for company-sponsored trials and future development. It reduces stated manufacturing time from 5–6 weeks to 22 days and produces cryopreserved product; clinical comparability, scale-up, cost, and regulatory acceptance remain unproven.
- In September 2017, Iovance sold 8.85 million shares for approximately $53.7 million net. In January 2018, it sold 15 million shares at $11.50 per share, with estimated net proceeds of approximately $161.7 million. The January financing is subsequent to year-end and dilutes existing shareholders.
Pipeline, outlook, and risks
- Lead program: LN-144 for metastatic melanoma is in a Phase 2 study. December 2017 cohort 2 results showed a preliminary 40% objective response rate among 10 evaluable patients; cohort 1 showed 29% among 16 evaluable patients. These are small, interim datasets, not evidence of approval or durable benefit.
- Other trials: LN-145 is being studied in head and neck and cervical cancers. Preliminary January 2018 head-and-neck data showed 3 partial responses among 8 treated patients (reported ORR 38%); cervical data showed 1 confirmed partial response and 1 case of stable disease among 2 evaluable patients. NSCLC studies and M.D. Anderson studies in additional cancers were planned or beginning in 2018.
- The FDA granted Fast Track designation for LN-144 in advanced melanoma; the company also has U.S. orphan-drug designation for specified melanoma stages. Neither designation assures approval or shortens the evidentiary requirements for approval.
- Management expected no product-sale or licensing revenue in 2018 and anticipated continued losses and increased R&D spending. Including the January 2018 offering proceeds, management believed available funds would cover anticipated operating expenses for at least 24 months from the filing date. This is an estimate dependent on spending, trial progress, and other factors.
- Key risks include clinical failure or changing interim results, adverse events, enrollment delays, Gen 2 process comparability and manufacturing scale-up, reliance on contract manufacturers and collaborators, regulatory uncertainty, competition, reimbursement and commercialization challenges, and potential future financing and dilution.
- Contingencies: The filing describes shareholder class and derivative litigation related to a 2017 SEC stock-promotion settlement, a dispute with Solomon Capital, a former executive’s lawsuit and company counterclaims, and possible claims concerning certain 2016 share resales. Loss amounts for these matters were not estimable in the filing. The company said it intended to defend the suits and did not expect pending matters to materially affect its financial position, results, or cash flows.
- The SEC settlement included a cease-and-desist order concerning securities-law provisions. The company disclosed that the order could constrain certain capital-raising activity and adversely affect its reputation. Separately, the 2017 Tax Act reduced the company’s deferred tax assets, with a corresponding valuation allowance; no income tax expense or benefit was reported for 2017.
Most important facts for investors to verify
- Updated, adequately sized trial results—including response durability, safety, and outcomes for patients treated with Gen 2—not just preliminary response rates.
- Regulatory feedback on a possible registration path for LN-144 and whether additional or confirmatory trials will be required.
- Manufacturing success rates, capacity, turnaround time, product consistency, and cost per patient as Gen 2 scales across contract manufacturers.
- Actual cash burn and remaining runway against management’s 24-month estimate, including the impact of expanding trials and the January 2018 equity issuance.
- Developments and potential financial exposure from the disclosed litigation and SEC order, as well as future dilution from outstanding equity awards, warrants, or financing.